RAINBOW

NCT01170663 📎

Regimen

Experimental
ramucirumab + paclitaxel
Control
placebo + paclitaxel

Population

Advanced gastric/GEJ adenocarcinoma progressing on first-line platinum/fluoropyrimidine

Key finding

mOS 9.6 vs 7.4 mo (HR 0.807, 95% CI 0.678-0.962, p=0.017); mPFS 4.4 vs 2.9 mo (HR 0.635, p<0.0001); ORR 28% vs 16%

Source: PMID 25240821

Timeline

    Guideline citations

    • NCCN GASTRIC (p.46)
    • CSCO GASTRIC 2025 (p.102)⚠️ OCR source